

29th Early Detection Research Network (EDRN) Steering Committee Meeting

March 31, 2015 – April 2, 2015

Emory Conference Center Hotel, Atlanta, Georgia

Objective: This meeting provides us with an opportunity to revisit several issues and projects needing refinement and will provide a framework for the next round of the EDRN. For example, we have had discussions that the definition of early detection research needs to be broadened to include progression of early lesions, detection of recurrent disease, etc. Similarly, we have previously identified a number of validation trials which should be finalized so that when the new round of EDRN commences, these projects could be readily selected for CORE fund support. Also, in the next round of EDRN, NCI would like to see more integration of “omic” approaches, particularly genomics, whole genome and targeted sequencing, and imaging in early detection research. The agenda for this meeting is drafted to encompass these activities.

Tuesday, March 31, 2015	
7:00 a.m. – 8:00 a.m.	Sign-In and Continental Breakfast
Opening Session Salon I & II	
8:00 a.m. – 8:10 a.m.	<u>Welcome</u> Walter J. Curran, Jr., Executive Director, Winship Cancer Institute of Emory University Lawrence W. Davis Professor and Chairman, Department of Radiation Oncology, Emory University School of Medicine NRG Oncology Group Co-Chairman, Georgia Research Alliance Eminent Scholar and Chair in Cancer Research
8:10 a.m. – 8:40 a.m.	<u>State of the EDRN</u> Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute Leslie Ford, M.D., National Cancer Institute
8:40 a.m. – 12:00 p.m.	Session 1: Clinicians’ Perspectives on the Role of Cancer Biomarkers Salon I & II Discussant: John Gohagan, Ph.D., National Institutes of Health Discussion of the clinical questions related to the unique clinical challenges surrounding early detection.
8:40 a.m. – 9:00 a.m.	<u>Colorectal Cancer</u> Robert Schoen, M.D., University of Pittsburgh
9:00 a.m.- 9:10 a.m.	Q&A
9:10 a.m.- 9:30 a.m.	<u>Pancreatic Cancer</u> Peter Allen, M.D., Memorial Sloan-Kettering Cancer Center
9:30 a.m. - 9:40 a.m.	Q&A
9:40 a.m. - 10:00 a.m.	Break
10:00 a.m.- 10:20 a.m.	<u>Lung Cancer</u> Harvey Pass, M.D., New York University School of Medicine
10:20 a.m. - 10:30 a.m.	Q&A
10:30 a.m. – 10:50 a.m.	<u>Prostate Cancer</u> Ian Thompson, M.D., The University of Texas Health Science Center San Antonio
10:50 a.m. - 11:00 a.m.	Q&A
11:00 a.m.– 11:20 a.m.	<u>Ovarian Cancer</u> Michael Birrer, M.D., Ph.D., Massachusetts General Hospital
11:20 a.m. - 11:30 a.m.	Q&A
11:30 a.m. - 11:50 a.m.	<u>Breast Cancer</u> Mary Daly, M.D., Ph.D., Fox Chase Cancer Center
11:50 a.m.- 12:00 p.m.	Q&A
12:00 p.m. – 12:10 p.m.	Special Presentation Salon I&II <u>Call for EDRN Labs to Participate in an Interlaboratory Study for Detection of Rare Mutations in Cell Free DNA in Biological Fluids</u> Kenneth D. Cole, Ph.D., National Institute of Standards and Technology
12:10 p.m.- 1:30 p.m.	Lunch (On Your Own)

29th Early Detection Research Network (EDRN) Steering Committee Meeting

March 31, 2015 – April 2, 2015

Emory Conference Center Hotel, Atlanta, Georgia

Tuesday, March 31, 2015 Continued	
1:30 p.m. - 5:30 p.m.	Session 2: Collaborative Group Meetings Discussants: Patient Advocates Elda Railey and Merel Grey Nissenberg Objective: The discussions will focus on validation trials, some of which are underway and some are currently being developed. This will enable the EDRN to use its CORE funds in a timely manner to support these trials when the new cycle of the EDRN begins. There will be some turnover in the next round, but in the event that a current investigator who is participating in a validation trial is not funded in the next round, CORE funds will be used to support their participation. NCI is seeking help in forming Implementation Committees that will work on these proposed validation trials to formalize them before the next cycle begins.
	Oak Amphitheatre Salon IV&V Salon III Salon I&II
	Breast and Gynecological Cancers Gastrointestinal Cancers Lung and Upper Aerodigestive Cancers Prostate and Genitourinary Cancers
7:00 p.m. – 9:00 p.m.	Data Sharing and Informatics Subcommittee Meeting Salon III
Wednesday, April 1, 2015	
7:00 a.m. – 8:00 a.m.	Sign-In and Continental Breakfast
8:00 a.m. – 11:20 a.m.	Session 3: Presentation of Collaborative Group Discussions Salon I&II
8:00 a.m. – 8:30 a.m.	<u>Breast and Gynecological Cancers</u> Steven Skates, Ph.D., Massachusetts General Hospital Karen Anderson, M.D., Ph.D., Arizona State University/The Biodesign Institute
8:30 a.m. – 8:40 a.m.	Q&A
8:40 a.m. – 9:10 a.m.	<u>Prostate and Urological Cancers</u> James Brooks, M.D., Stanford University
9:10 a.m. – 9:20 a.m.	Q&A
9:20 a.m.– 9:40 a.m.	Break
9:40 a.m. – 10:10 a.m.	<u>Lung and Upper Aerodigestive Cancers</u> Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center Avrum Spira, M.D., Boston University
10:10 a.m.– 10:20 a.m.	Q&A
10:20 a.m. – 11:10 a.m.	<u>Gastrointestinal Cancers</u> Michael (Tony) Hollingsworth, Ph.D., University of Nebraska Medical Center Dean Brenner, M.D., University of Michigan
11:10 a.m.– 11:20 a.m.	Q&A
11:20 a.m. – 12:20 p.m.	Invited Presentations Salon I&II
11:20 a.m. – 11:50 a.m.	<u>The Baseline Study of Health and the Transition to Disease</u> Vik Bajaj, Ph.D., Google Life Sciences
11:50 a.m. – 12:20 p.m.	<u>Generation and Use of Quantitative Pathology Phenotype</u> Joel Saltz, M.D., Ph.D., Stony Brook University
12:20 p.m. - 2:00 p.m.	Lunch (On Your Own)
12:20 p.m. - 2:00 p.m.	Executive Committee Meeting (closed session) Salon IV&V
2:00 p.m. – 5:00 p.m.	Session 4: Cross-Organ Site Collaboration on Overarching Clinical Questions Objective: These concurrent sessions will be devoted to identifying topics and areas of research that are applicable to a variety of tumor types. It is like “repurposing” a drug. Discussions will focus on markers and other molecular profiles that are applicable across tumor types and the integration of these markers with imaging. The groups will also discuss potential studies designed to test biomarker effectiveness in a variety of tumors at one time.

29th Early Detection Research Network (EDRN) Steering Committee Meeting

March 31, 2015 – April 2, 2015

Emory Conference Center Hotel, Atlanta, Georgia

Wednesday, April 1, 2015 Continued	
2:00 p.m. – 5:00 p.m.	Session 4: Cross-Organ Site Collaboration on Overarching Clinical Questions Continued
2:00 p.m. – 5:00 p.m. Salon I&II	<p><u>Targeted Sequencing & ncRNA</u> Chair: Avi Spira, M.D., Boston University Discussants:</p> <ul style="list-style-type: none"> • Carlo Croce, M.D., The Ohio State University • Harvey Pass, M.D., New York University School of Medicine • Arul Chinnaiyan, M.D., Ph.D., The University of Michigan • David Sidransky, M.D., J Johns Hopkins University School of Medicine • Sanford Markowitz, M.D., Case Western Reserve University • Karl Krueger, Ph.D., National Cancer Institute • Jo Ann Rinaudo, Ph.D., National Cancer Institute • Lynn Sorbara, Ph.D., National Cancer Institute • Matthew Young, Ph.D., National Cancer Institute • Wendy Wang, Ph.D., National Cancer Institute
2:00 p.m. – 5:00 p.m. Oak Amphitheatre	<p><u>Microenvironment</u> Chair: Subrata Sen, Ph.D., The University of Texas MD Anderson Cancer Center Discussants:</p> <ul style="list-style-type: none"> • Michael (Tony) Hollingsworth, Ph.D., University of Nebraska Medical Center • Hemant Roy, M.D., Boston University • Vadim Backman, Ph.D., Northwestern University • Michael Birrer, M.D., Ph.D., Harvard Medical School • Dan Mercola, M.D., Ph.D., University of California, Irvine • Joel Saltz, M.D., Ph.D., Stony Brook University • Steven Dubinett, M.D., University of California, Los Angeles • Jacob Kagan, M.Sc., Ph.D., National Cancer Institute • Christos Patriotis, Ph.D., National Cancer Institute • Nada Vydelingum, Ph.D., National Cancer Institute • Richard Mazurchuk, Ph.D., National Cancer Institute
Thursday, April 2, 2015	
7:00 a.m. – 8:00 a.m.	Sign-In and Continental Breakfast
8:00 a.m. – 11:30 a.m.	Session 5: Revisiting EDRN Policy and Procedures (closed Session - Steering Committee Members only) Salon I&II
<p><u>Objective:</u> Prior to the Steering Committee meeting, NCI Program Directors will contact the Chairs and Co-Chairs of the EDRN Policy Subcommittees to review existing policies and procedures pertaining to collaboration, release of set-asides, usage of CORE funds and other challenging issues that we have encountered during the last ten years. Modifications and amendments will be presented to the entire Steering Committee for discussion and approval.</p> <p><u>Collaboration and Publication Subcommittee</u> Lynn Sorbara, Ph.D., National Cancer Institute</p> <p><u>Data Sharing and Informatics Subcommittee</u> Christos Patriotis, Ph.D., National Cancer Institute</p> <p><u>Prioritization Subcommittee</u> Karl Krueger, Ph.D., and Jo Ann Rinaudo, Ph.D., National Cancer Institute</p> <p><u>Technology and Resource Sharing Subcommittee</u> Jacob Kagan, M.Sc., Ph.D., and Sharmistha Ghosh-Janjigian, Ph.D., National Cancer Institute</p>	
11:30 a.m.	Adjourn